Allogeneic Clinical Trials

64 recruitingLast updated: July 25, 2026

There are 64 actively recruiting allogeneic clinical trials across 14 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1, Phase 4. Top locations include Boston, Massachusetts, United States, New York, New York, United States, Cleveland, Ohio, United States. Updated daily from ClinicalTrials.gov.


Allogeneic Trials at a Glance

64 actively recruiting trials for allogeneic are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 2 with 25 trials, with the heaviest enrollment activity in Boston, New York, and Cleveland. Lead sponsors running allogeneic studies include Children's Hospital Medical Center, Cincinnati, Royal Brisbane and Women's Hospital, and Center for International Blood and Marrow Transplant Research.

Browse allogeneic trials by phase

Treatments under study

About Allogeneic Clinical Trials

Looking for clinical trials for Allogeneic? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Allogeneic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Allogeneic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 64 trials

Recruiting
Phase 3

Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

allogeneic stem cell transplantationCardiovascular DiseasesAcute Lung Injury+3 more
National Heart, Lung, and Blood Institute (NHLBI)210 enrolled1 locationNCT07613099
Recruiting

Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation

Allogeneic Transplantation
M.D. Anderson Cancer Center1,200 enrolled1 locationNCT06450353
Recruiting
Phase 3

Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donors

Healthy Hematopoietic Stem Cell DonorHealthy Allogeneic Hematopoietic Stem Cell Donor
First Affiliated Hospital of Zhejiang University560 enrolled8 locationsNCT07692841
Recruiting

Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
National Heart, Lung, and Blood Institute (NHLBI)40 enrolled1 locationNCT06093867
Recruiting
Phase 4

Improving White Blood Cell Collection From Healthy Donors

Allogeneic Granulocyte Donation
National Institutes of Health Clinical Center (CC)1,000 enrolled1 locationNCT01553214
Recruiting
Phase 2

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation
Children's Hospital Medical Center, Cincinnati60 enrolled1 locationNCT05501756
Recruiting
Early Phase 1

Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation
Case Comprehensive Cancer Center20 enrolled1 locationNCT04332341
Recruiting
Early Phase 1

Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Mari Dallas20 enrolled1 locationNCT03378102
Recruiting
Phase 3

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Phase 2Phase 3

VABu Conditioning in Elderly AML HSCT

Acute Myeloid Leukemia (AML)Allogeneic Hematopoietic Stem Cell Transplantation Recipient
The First Affiliated Hospital of Soochow University20 enrolled1 locationNCT07583888
Recruiting
Phase 2

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting

APOLLO: Personalized rehAbilitation PrOgram in aLLOgeneic Bone Marrow Transplantation

Allogeneic Disease
University of Alberta45 enrolled1 locationNCT05579678
Recruiting
Phase 2

Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Acute Graft Versus Host DiseaseGraft-Versus-Host DiseaseALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology42 enrolled1 locationNCT07572669
Recruiting

Longitudinal Cohort Study on Invasive Fungal Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Invasive Fungal DiseaseAllogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Peking University People's Hospital6,000 enrolled1 locationNCT07569055
Recruiting
Phase 2

Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant

allogeneic stem cell transplantation
Children's Hospital Medical Center, Cincinnati419 enrolled3 locationsNCT05579639
Recruiting
Not Applicable

Nutrition OUtReach In Systems of Healthcare

CAR-T Cell TherapyALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONFood Insecurity+1 more
University of Kansas Medical Center210 enrolled4 locationsNCT06802406
Recruiting
Early Phase 1

Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

Allogeneic Hematopoietic Stem Cell Transplantation RecipientAdenovirusCytomegalovirus+2 more
Sumithira Vasu20 enrolled2 locationsNCT03665675
Recruiting
Phase 1Phase 2

Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS

Proton TherapyAcute Myeloid Leukemia (AML)Myelodysplastic Neoplasm+2 more
Institute of Hematology and Blood Transfusion, Czech Republic16 enrolled2 locationsNCT07532824
Recruiting
Phase 1

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Acute LeukemiaMyelodysplastic SyndromesMyeloproliferative Disorders+3 more
Stanford University77 enrolled1 locationNCT05088356
Recruiting
Phase 2

Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention

Graft-Versus-Host-Disease (GVHD)allogeneic stem cell transplantationHematologic Malignancies
Milton S. Hershey Medical Center41 enrolled1 locationNCT06926595